Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer.
about
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune DiseasesThe Role of HMGB1 Signaling Pathway in the Development and Progression of Hepatocellular Carcinoma: A ReviewDamage-associated molecular patterns in cancer: a double-edged swordHMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cellsPlasma free amino acid profiling of five types of cancer patients and its application for early detectionAlarmins: awaiting a clinical responseHigh-mobility group box 1 and cancer.Antitumor immunity induced after α irradiationPrognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas.Diagnostic significance of serum HMGB1 in colorectal carcinomasThe "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2008-09.Identification and characterization of the lamprey high-mobility group box 1 gene.HMGB1 in health and disease.High mobility group box-1 and its clinical value in breast cancer.Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2.High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis.Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies.Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiationPrognostic Significance of Tag SNP rs1045411 in HMGB1 of the Aggressive Gastric Cancer in a Chinese Population.Relationship between high-mobility group box 1 overexpression in ovarian cancer tissue and serum: a meta-analysis.Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation.Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patientsHelicobacter pylori Activates HMGB1 Expression and Recruits RAGE into Lipid Rafts to Promote Inflammation in Gastric Epithelial Cells.Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese populationHMGB1 level in cerebrospinal fluid as a complimentary biomarker for the diagnosis of tuberculous meningitisDysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer.HMGB1 in hormone-related cancer: a potential therapeutic target.Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression.Combined targeting of high-mobility group box-1 and interleukin-8 to control micrometastasis potential in gastric cancer.HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarminsTargeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference.Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells.Gene expression disorders of innate antibacterial signaling pathway in pancreatic cancer patients: implications for leukocyte dysfunction and tumor progressionExpression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinomaHMGB1: A Promising Therapeutic Target for Prostate Cancer.High-mobility group box-1 contributes tumor angiogenesis under interleukin-8 mediation during gastric cancer progression.A multicenter matched case-control analysis on seven polymorphisms from HMGB1 and RAGE genes in predicting hepatocellular carcinoma risk.Correlation of HMGB1 expression to progression and poor prognosis of adenocarcinoma and squamous cell/adenosquamous carcinoma of gallbladder.Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.
P2860
Q26768480-DB407F22-9EDD-40DC-ABC6-9062736E1388Q26782281-0414580C-8E27-4AB9-86AF-5C6BF8C93987Q28067434-A055D86D-6A3E-482B-84F2-2A4B145B47E0Q28117763-6F87CF05-1EC3-4C17-8B4F-0F9AD86F14E3Q28740654-8B601539-BD60-4906-9B4B-DA415B100918Q30523797-73E98F9F-AFCD-42A8-933D-237DA84869B2Q33638306-7DFDB146-AB16-4838-85E8-25BFB03E4E48Q33891246-BB034444-44BE-4859-96F7-6B301ADBF7E7Q34019875-4872DDF4-93AB-4BC3-AA9D-E93515F21B2AQ34230026-8E7FE4D5-9B27-4D86-987B-88A495F3CC09Q34243570-F65D33F1-3A55-443B-84B2-C0D0C5A635D5Q34259728-6901678A-C9B5-46F8-8206-99FB98A467C7Q34622835-7CAC9628-DE02-47C3-9085-EFEEAF9A49FBQ35101004-96ABAB87-345E-458C-B5CB-280E2CD0BFB5Q35172545-26403A6F-B67C-443D-A232-8F5477FDEC00Q35188596-0CBABF3C-5671-4576-9F3D-16E71A368877Q35406168-C6806B80-D3FE-4702-A7C3-0D41945FD72DQ35545467-E2AEC4A4-13AA-4AE8-9915-BF466FBBC2D2Q35591847-9CD3BBAD-D179-43C6-A954-8A4F96F701E8Q35999764-2BB5B95D-79B3-46E0-887B-8CEE0C707254Q36347619-7BAF0AEB-52B7-4353-BCC3-DAF2F31489CDQ36985164-39B0D844-AFAF-4DBA-AEC1-2118ADE5C3ADQ37071863-5BB047CB-F2B3-475C-9F0C-E2796D3C5EA5Q37242901-FFA217FF-A267-4466-94CE-23DD6CEA0C7EQ37251612-0527038D-DBF8-4715-9D03-B6097C276ADBQ37334747-19199CB5-2BD4-49D3-B67A-D289F5AB18B1Q37739809-DE286F6B-32B3-49C4-8BBF-B63A536A6454Q38203471-FDD7BC05-B1D2-4B02-A1E6-D0675E93799BQ38855171-8BA51920-0BD1-4DC7-AAC4-EC88C11E9F66Q38893404-23A5BE29-B534-4A42-B8E6-DFCA8B874028Q38939435-E61D2922-74AC-43C7-8CCA-1802F54012D6Q39396939-C3263484-296C-4106-9383-88F6D3D0B4A7Q39467052-B740B235-17AE-42E7-8F7F-7962112A9B61Q40923346-C245B0FA-22CB-4254-A332-58FA21EC9A20Q40978463-FC30DD10-2807-41C7-9D0C-C46C59D7EE3BQ41136849-2CDB7816-EF22-4852-92CD-8FB9684A1BA6Q41248552-1AA2B212-6B5B-484F-B122-B86264A8DB43Q41472938-A28C9F0A-4550-4F3D-BDC3-0C8C563F3654Q42068869-2EF4BA2A-7845-4CC4-B961-E2BF1C11EEBAQ44844478-B818B8AA-E491-43DA-B04A-B98D12C8AA3C
P2860
Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serum high mobility group box- ...... ic features of gastric cancer.
@en
Serum high mobility group box-1
@nl
type
label
Serum high mobility group box- ...... ic features of gastric cancer.
@en
Serum high mobility group box-1
@nl
prefLabel
Serum high mobility group box- ...... ic features of gastric cancer.
@en
Serum high mobility group box-1
@nl
P2093
P2860
P356
P1476
Serum high mobility group box- ...... ic features of gastric cancer.
@en
P2093
David Stroncek
Duck Jin Hong
Heejung Kim
Hye Won Chung
Jae Bock Chung
Jong-Baeck Lim
Sang-Guk Lee
P2860
P2888
P356
10.1186/1479-5876-7-38
P577
2009-05-28T00:00:00Z
P5875
P6179
1051265448